Module

Novel Developments in the Treatment of Malignant Mesothelioma

Source: Novel Developments in the Treatment of Malignant Mesothelioma

Novel Developments in the Treatment of Malignant Mesothelioma

Faculty:

Marcelo C. DaSilva, MD, FACS, FCCP
David J. Sugarbaker, MD

CREDIT INFORMATION

Release Date: 01/26/10

Expiration Date: 01/25/11

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the epidemiological patterns, pathogenesis, and histology of mesothelioma
Articulate the key diagnostic features of malignant pleural mesothelioma
Cite clinical trial data supporting the use of specific first-line chemotherapy regimens and the role of multimodality therapy for the treatment of malignant pleural mesothelioma
Discuss recent data on emerging targeted agents for the treatment of malignant pleural mesothelioma

Topics covered include:

Epidemiology and Pathogenesis of Mesothelioma
Anatomy and Histologic Subtypes of Mesothelioma
Clinical Presentation and Diagnosis of Metastatic Pleural Mesothelioma
Staging of Malignant Pleural Mesothelioma
Current Treatment Options
Current Treatment Options: Surgery
Current Treatment Options: Multimodality Therapy
Current Treatment Options: Chemotherapy
Current Treatment Options: Targeted Biologic Therapy
The Future of Mesothelioma Treatment
Conclusion

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.